FDA Grants Priority Review to Epcoritamab-bysp for Relapsed

If approved, epcoritamab (DuoBody CD3xCD20; AbbVie, Genmab) would be the first and only subcutaneous bispecific antibody for treatment in this patient population.

Related Keywords

United States , American , Epcoritamab Epkinly Tepkinly , Epcoritamab Duobody , Mariana Cota Stirner , European Medicines Agency , Exposition Of The American Society Hematology , Drug Administration , Cota Stirner , Annual Meeting , American Society , Drug Administration Grants Priority Review , Difficult To Treat Relapsed , Refractory Follicular Lymphoma , Bispecific Antibody Epcoritamab , Shows Strong , Durable Treatment Response , Follicular Lymphoma , Refractory Follicular ,